This study investigated the use of targeted drugs after OncoFOCUSTM+KIT screening in patients with malignant melanoma, non-small cell lung cancer and metastatic colorectal cancer, and then audited the results against the National Comprehensive Cancer Network (NCCN) guidelines. This evidence concerns the gene KIT and metastatic colorectal cancer.